Helicobacter Pylori Infection
H.pylori is a gram-negative bacterium that has been implicated in a number of gastrointestinal pathologies.
| Pathology | Details |
|---|---|
| Chronic gastritis | H. pylori can predispose patients to other conditions, such as neoplasm |
| Peptic ulcer disease | H. pylori has been implicated in:
|
| Gastric adenocarcinoma | H. pylori associated with a 1-2% lifetime risk of gastric adenocarcinoma |
| B cell lymphoma of MALT tissue | 75% of MALT lymphomas are successfully treated with H. pylori eradication therapy |
Table 9: Sequelae of chronic Helicobacter pylori infection.
Investigations (BSG guidelines)
- 1st line: Urea breath test/stool antigen testing
- Requires a 2-week PPI washout period and 4 weeks for antibiotics
- Urea breath test is the preferred investigation to test for eradication post treatment
- 2nd line: Serology (does not differentiate between active and past infection, so cannot be used for retesting)
If a patient is undergoing OGD, the endoscopist can take biopsies to perform a rapid urease test (also known as the CLO test – Campylobacter-Like Organism) to test for H. pylori.
Treatment
7 days high-dose PPI + amoxicillin + metronidazole/clarithromycin
- If the patient is penicillin allergic, use high-dose PPI + metronidazole + clarithromycin (7 days).
Antiulcer medication
Reduction/neutralisation of stomach acid:
- Proton pump inhibitors (antisecretory)
- Histamine-2 receptor antagonists (antisecretory)
- Antacids (neutralising)
Other mechanisms:
- Sucralfate (forms a protective barrier over the ulcer)
Take your subscriptions with you
Our mobile app allows you to access your interview and exam question banks wherever you are.